What type of study is this?

This is a Cohort Study study (also classified as: Pre-Registered Trial).

Nab-paclitaxel-based chemotherapy with or without anti-PD-(L)1 immunotherapy as a second-line treatment for advanced biliary tract cancer: a real-world retrospective study

View Full Paper

Ask AI

Bookmark

Authors

Real-world study finds nab-paclitaxel shows promising efficacy in biliary tract cancer patients, highlighting the impact of second-line treatment.

Overall survival was assessed, showing a median of 15.17 months in the entire patient cohort.
Nab-paclitaxel chemotherapy indicated a 21.4% response rate and notable adverse events relevant to treatment effectiveness.
The retrospective analysis covered patients treated at West China Hospital over five years, focusing on therapy comparisons.
Findings suggest nab-paclitaxel is a promising option for second-line treatment in biliary tract cancer, implying further exploration is warranted.

Zhou et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Real-world study finds nab-paclitaxel shows promising efficacy in biliary tract cancer patients, highlighting the impact of second-line treatment.

Overall survival was assessed, showing a median of 15.17 months in the entire patient cohort.
Nab-paclitaxel chemotherapy indicated a 21.4% response rate and notable adverse events relevant to treatment effectiveness.
The retrospective analysis covered patients treated at West China Hospital over five years, focusing on therapy comparisons.
Findings suggest nab-paclitaxel is a promising option for second-line treatment in biliary tract cancer, implying further exploration is warranted.

Zhou et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark